Cell surface remodeling by plasmin: a new function for an old enzyme

EI Deryugina, JP Quigley - BioMed Research International, 2012 - Wiley Online Library
Plasmin, one of the most potent and reactive serine proteases, is involved in various
physiological processes, including embryo development, thrombolysis, wound healing and …

Emerging photodynamic/sonodynamic therapies for urological cancers: progress and challenges

X Hu, YS Zhang, YC Liu, N Wang, XT Zeng… - Journal of …, 2022 - Springer
Photodynamic therapy (PDT), and sonodynamic therapy (SDT) that developed from PDT,
have been studied for decades to treat solid tumors. Compared with other deep tumors, the …

Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression

J Hao, H Chen, MC Madigan, PJ Cozzi… - British journal of …, 2010 - nature.com
Background: The aim of this study is to seek an association between markers of metastatic
potential, drug resistance-related protein and monocarboxylate transporters in prostate …

Surface α-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target

KC Hsiao, NY Shih, HL Fang, TS Huang, CC Kuo… - PloS one, 2013 - journals.plos.org
In previous research, we found α-enolase to be inversely correlated with progression-free
and overall survival in lung cancer patients and detected α-enolase on the surface of lung …

[HTML][HTML] Downregulation of CFTR promotes epithelial-to-mesenchymal transition and is associated with poor prognosis of breast cancer

JT Zhang, XH Jiang, C Xie, H Cheng, J Da Dong… - … et Biophysica Acta (BBA …, 2013 - Elsevier
The epithelial-to-mesenchymal transition (EMT), a process involving the breakdown of cell–
cell junctions and loss of epithelial polarity, is closely related to cancer development and …

Prostate cancer relevant antigens and enzymes for targeted drug delivery

A Barve, W Jin, K Cheng - Journal of Controlled Release, 2014 - Elsevier
Chemotherapy is one of the most widely used approaches in combating advanced prostate
cancer, but its therapeutic efficacy is usually insufficient due to poor specificity and …

CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer

C Xie, XH Jiang, JT Zhang, TT Sun, JD Dong… - Oncogene, 2013 - nature.com
Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) is expressed in the
epithelial cells of a wide range of organs/tissues from which most cancers are derived …

Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy

AP Mazar - Clinical cancer research, 2008 - AACR
The urokinase plasminogen activator receptor (uPAR) has been implicated in the growth,
metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is part …

An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro …

SA Rabbani, B Ateeq, A Arakelian, ML Valentino… - Neoplasia, 2010 - Elsevier
Urokinase plasminogen activator receptor (uPAR) is a multidomain protein that plays
important roles in the growth, invasion, and metastasis of a number of cancers. In the …

Targeting uPA/uPAR in prostate cancer

Y Li, PJ Cozzi - Cancer Treatment Reviews, 2007 - Elsevier
Prostate cancer (CaP) is one of the most common malignancies in men, with an increasing
incidence. Despite significant advances in surgery, chemotherapy and radiotherapy to treat …